Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-032
Official listed status: posted
Closing information: 2027-01-07 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Private institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; For profit organizations other than small businesses; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments)
Federal synopsis
This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.